Rise of Methamphetamine: New Risks, Current Treatment | Rick Rawson, PhD
This presentation is part of the 2020 State of the Art in Addiction Medicine conference which covers an expansion of treatment into correctional health, hospital consultation services and emergency rooms. It will cover how, despite the pandemic, telehealth can reach those who are isolated. It will address the worrisome trends in fentanyl, methamphetamine, tobacco and benzodiazepines use; legalization of cannabis, treatment updates for youth, cannabis and alcohol in pregnant women; and novel treatments such as non-benzodiazepines for alcohol withdrawal and psychedelics for substance use disorders.
Learners cannot sign up for individual lectures, only for the full 2020 State of the Art in Addiction Medicine. Please contact CSAM (firstname.lastname@example.org) if you have any questions about this online educational offering.
Addiction medicine specialists who want an overview of the latest developments in the field and their relevance to clinical practice
- Primary care, psychiatry and other specialty field clinicians who want a better understanding of addiction and to improve their care of patients with unhealthy substance use
- Public policy makers, administrators and advocates who want an understanding of the current state of the field of addiction and its grater implications including towards prevention, access to care, integrated systems of care and healthcare technology
- Other healthcare professionals, including psychologists, therapists, nurses, and addiction counselors, who are involved in the treatment of patients with or at risk of substance use
- Participants will be able to explain the current epidemiology of cocaine and methamphetamine in the US
- Participants will be able to describe the most common clinical challenges in treatment people with stimulant use disorders.
- Participants will be able to review and discuss the current evidence-based practices for the treatment of individuals with stimulant use disorder.
Richard Rawson, PhD
Richard A. Rawson, Ph.D., is Professor Emeritus at the UCLA Department of Psychiatry and a Research Professor at the Vermont Center for Behavior and Health at the University of Vermont. He received a Ph.D. in experimental psychology from the University of Vermont in 1974. Dr. Rawson conducted numerous clinical trials on pharmacological and psychosocial/behavioral addiction treatments for the treatment of individuals with cocaine and methamphetamine disorders. He was a member of the Federal Methamphetamine Advisory Group to Attorney General Janet Reno (1996-2000) and represented the US at numerous international meetings on methamphetamine. He has led addiction research and training projects for the United Nations, the World Health Organization and the U.S. State Department, exporting science-based knowledge to many parts of the world. Dr. Rawson has published 3 books, 40 book chapters, and over 250 peer-reviewed articles and has conducted over 1,000 workshops, paper presentations, and training sessions.
DISCLOSURE: No relevant financial relationships to disclose
The California Society of Addiction Medicine (CSAM) is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.
CSAM designates this live educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™, Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing education credit is available for psychologists, therapists, substance use counselors, nurses and physician assistants.
(see additional information on page for parent course)
- 0.75 AMA Category 1
- 0.75 Attendance